Neogenomics (NEO) Liabilities and Shareholders Equity (2016 - 2025)
Neogenomics (NEO) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $1.4 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 16.98% year-over-year to $1.4 billion, compared with a TTM value of $5.7 billion through Dec 2025, down 12.69%, and an annual FY2025 reading of $1.4 billion, down 16.98% over the prior year.
- Liabilities and Shareholders Equity was $1.4 billion for Q4 2025 at Neogenomics, down from $1.4 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.9 billion in Q3 2021 and bottomed at $1.4 billion in Q4 2025.
- Average Liabilities and Shareholders Equity over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2023.
- The sharpest move saw Liabilities and Shareholders Equity surged 7379.11% in 2021, then decreased 16.98% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $1.9 billion in 2021, then fell by 6.94% to $1.7 billion in 2022, then decreased by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then fell by 16.98% to $1.4 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for NEO at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.4 billion in Q2 2025.